Wentilactone B from Aspergillus wentii induces apoptosis and inhibits proliferation and migration of human hepatoma SMMC-7721 cells

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 11, 2012, Pages 1964-1971

  Zhang, Zhenwei ^a   Miao, Lei ^b   Sun, Weizhang ^c   Jiao, Binghua ^a   Wang, Bingui ^d   Yao, Li ^b   Huang, Caiguo ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^c CHENGDU MILITARY GENERAL HOSPITAL   (China)

^d INSTITUTE OF OCEANOLOGY   (China)

Author keywords

Apoptosis; Chang; Migration; SMMC 7721; Wentilactone B

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; ANTIFUNGAL AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; HERMES ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG; WENTILACTONE B;

ANTIFUNGAL ACTIVITY; APOPTOSIS; ARTICLE; ASPERGILLUS WENTII; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG STRUCTURE; FLOW CYTOMETRY; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL; METASTASIS INHIBITION; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ASPERGILLUS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84869216292     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00368     Document Type: Article

References (30)

1. Halsey C, Lumley H, Luckit J. Necrotising external otitis caused by Aspergillus wentii: a case report. Mycoses, 54, e211-e213 (2011).
2. Sun HF, Li XM, Meng L, Cui CM, Gao SS, Li CS, Huang CG, Wang BG. Asperolides A-C, tetranorlabdane diterpenoids from the marine alga-derived endophytic fungus Aspergillus wentii EN-48. J. Nat. Prod., 75, 148-152 (2012).
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin., 61, 69-90 (2011).
4. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: world-wide incidence and trends. Gastroenterology, 127, S5-S16 (2004).
5. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, Wong J. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann. Surg., 234, 63-70 (2001).
6. Lawen A. Apoptosis-an introduction. Bioessays, 25, 888-896 (2003).
7. Lock-Andersen J, Horn J, Sjøstrand H. Prognosis after sentinel node biopsy in malignant melanoma. Ugeskr. Laeger, 168, 2457-2462 (2006).
8. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer, 2, 277-288 (2002).
9. Eberle J, Kurbanov BM, Hossini AM, Trefzer U, Fecker LF. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Drug Resist. Updat., 10, 218-234 (2007).
10. Schimmer AD. Novel therapies targeting the apoptosis pathway for the treatment of acute myeloid leukemia. Curr. Treat. Options Oncol, 8, 277-286 (2007).
11. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell, 140, 883-899 (2010).
12. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG. Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer, 12, 39-50 (2012).
13. Natsuizaka M, Omura T, Akaike T, Kuwata Y, Yamazaki K, Sato T, Karino Y, Toyota J, Suga T, Asaka M. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J. Gastroenterol. Hepatol., 20, 1781-1787 (2005).
14. Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K, Hiramatsu A, Kodama H, Takahashi S, Chayama K. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J. Gastroenterol., 13, 414-420 (2007).
15. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet, 353, 1253-1257 (1999).
16. Iorio MV, Casalini P, Piovan C, Di Leva G, Merlo A, Triulzi T, Ménard S, Croce CM, Tagliabue E. microRNA-205 regulates HER3 in human breast cancer. Cancer Res., 69, 2195-2200 (2009).
17. Zhang ZW, Zhang JP, Miao L, Liu K, Yang SS, Pan CY, Jiao BH. Interleukin-11 promotes the progress of gastric carcinoma via abnormally expressed versican. Int. J. Biol. Sci., 8, 383-393 (2012).
18. Murphy KM, Ranganathan V, Farnsworth ML, Kavallaris M, Lock RB. Bc1-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells. Cell Death Differ., 7, 102-111 (2000).
19. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ. Movement of Bax from the cytosol to mitochondria during apoptosis. J. Cell Biol., 139, 1281-1292 (1997).
20. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM. Regulation of cancer cell migration and bone metastasis by RANKL. Nature, 440, 692-696 (2006).
21. Akbar SM, Abe M, Murakami H, Tanimoto K, Kumagi T, Yamashita Y, Michitaka K, Horiike N, Onji M. Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis; relevance to pathogenesis. Cancer Lett., 171, 125-132 (2001).
22. Xia Y, Chen R, Ye SL, Sun R, Chen J, Zhao Y. Inhibition of T-cell responses by intratumoral hepatic stellate cells contribute to migration and invasion of hepatocellular carcinoma. Clin. Exp. Metastasis, 28, 661-674 (2011).
23. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv. Cancer Res., 71, 241-319 (1997).
24. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. MP, Mol. Pathol., 52, 189-196 (1999).
25. Li F, Tiede B, Massagué J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res., 17, 3-14 (2007).
26. Alves CS, Burdick MM, Thomas SN, Pawar P, Konstantopoulos K. The dual role of CD44 as a functional P-selectin ligand and fibrin receptor in colon carcinoma cell adhesion. Am. J. Physiol. Cell Physiol, 294, C907-C916 (2008).
27. Ahmed N, Thompson EW, Quinn MA. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J. Cell. Physiol., 213, 581-588 (2007).
28. Hudson LG, Zeineldin R, Stack MS. Phenotypic plasticity of neoplastic ovarian epithelium: unique Cadherin profiles in tumor progression. Clin. Exp. Metastasis, 25, 643-655 (2008).
29. Zeineldin R, Muller CY, Stack MS, Hudson LG. Targeting the EGF receptor for ovarian cancer therapy. J. Oncol., 2010, 1-11 (2010).
30. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer, 8, 11-31 (2001).